The Phase 3 success and imminent NDA submission represent a major de-risking event for AMLX. Monitor the investor call for commercial launch preparation details and regulatory pathway clarity. The stock likely re-rates significantly on the removal of PBH regulatory risk and the potential first-to-market position in a clear unmet need.
Price Chart
Executive Summary
Amylyx announced highly positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH), meeting the FDA-agreed primary endpoint with a 55% reduction in hypoglycemic events (p=0.000003) and all secondary endpoints. The company plans to submit an NDA to the FDA by year-end 2026 with a potential commercial launch in 2027 if approved. This de-risks the PBH program significantly and opens a path to the first approved therapy for an estimated 160,000 U.S. patients, making this a transformative catalyst for the stock.
Key Facts
- Phase 3 LUCIDITY trial (n=78) met FDA-agreed primary endpoint: 55% reduction in composite rate of Level 2 and Level 3 hypoglycemic events vs placebo (p=0.000003)
- All secondary endpoints met with highly statistically significant and clinically meaningful reductions across SMBG, CGM, and adjudicated Level 3 events
- Avexitide was generally well-tolerated with no serious adverse events related to treatment; most common AEs were diarrhea, injection site erythema, bruising
- Company plans to submit NDA to FDA by end of 2026; avexitide has Breakthrough Therapy Designation for PBH and Orphan Drug Designation for hyperinsulinemic hypoglycemia
- PBH estimated to affect ~8% of U.S. patients post-bariatric surgery (~160,000 people); no FDA-approved therapies currently exist
- Investor conference call scheduled for August 18, 2026 at 8:00 AM ET
- FDA previously granted Breakthrough Therapy Designation for avexitide in PBH
Financial Impact
No revenue or financial figures provided in filing; market opportunity is an estimated 160,000 U.S. PBH patients with no approved therapy
Risk Factors
- NDA submission and FDA review remain subject to regulatory uncertainty despite Breakthrough Therapy designation
- Commercial adoption may depend on pricing, reimbursement, and market education in a niche indication
- Competition from off-label or emerging therapies could emerge before or after potential approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-354716 |
| Document: d180533dex991.htm | 0001193125-26-354716 |
| Document: 0001193125-26-354716-index-headers.html | 0001193125-26-354716 |
| Document: 0001193125-26-354716-index.html | 0001193125-26-354716 |
| Document: 0001193125-26-354716.txt | 0001193125-26-354716 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 144 | $28.04 | awaiting T+20 | — | $27.09 (−3.39%) |
Sep 14, 2026 6w ago | Insider Cluster | $33.15 $26.85 | ▼ −19.00% | ▼ −21.73% | $27.09 (−18.28%) |
Sep 11, 2026 6w ago | 144 | $33.64 $27.48 | ▼ −18.31% | ▼ −20.57% | $27.09 (−19.47%) |
Aug 18, 2026 9w ago | 8-K | $35.11 $33.05 | ▼ −5.87% | ▼ −4.88% | $27.09 (−22.84%) |
Aug 15, 2026 10w ago | Institutional Cluster | $21.43 $33.15 | ▲ +54.69% | ▲ +56.67% | $27.09 (+26.41%) |
Aug 6, 2026 11w ago | 8-K | $24.19 $33.96 | ▲ +40.39% | ▲ +39.79% | $27.09 (+11.99%) |
Jun 11, 2026 19w ago | Institutional Cluster | $13.91 $18.38 | ▲ +32.14% | ▲ +30.24% | $27.09 (+94.75%) |
Apr 23, 2026 26w ago | DEFA14A | $17.32 $13.61 | ▼ −21.42% | ▼ −26.05% | $27.09 (+56.41%) |
Mar 2, 2026 34w ago | Insider Cluster | $15.30 $12.76 | ▼ −16.60% | ▼ −8.66% | $27.09 (+77.06%) |
Feb 23, 2026 35w ago | Insider Cluster | $13.90 $13.53 | ▲ +2.66% | ▼ −1.28% | $27.09 (−94.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers